AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) shares gapped down prior to trading on Friday. The stock had previously closed at $47.77, but opened at $45.27. AnaptysBio shares last traded at $46.1150, with a volume of 42,460 shares changing hands.
Wall Street Analysts Forecast Growth
ANAB has been the subject of a number of research analyst reports. Wolfe Research reissued an “outperform” rating and set a $78.00 price target on shares of AnaptysBio in a report on Monday, August 31st. Cantor Fitzgerald restated an “overweight” rating on shares of AnaptysBio in a research report on Tuesday, September 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $95.00 price objective on shares of AnaptysBio in a research note on Tuesday, September 22nd. JPMorgan Chase & Co. decreased their target price on AnaptysBio from $70.00 to $60.00 and set an “overweight” rating on the stock in a research report on Wednesday, September 30th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of AnaptysBio in a research report on Wednesday, November 4th. Twelve research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $75.67.
Check Out Our Latest Report on AnaptysBio
AnaptysBio Stock Performance
The firm has a market cap of $1.38 billion, a P/E ratio of 9.32 and a beta of 0.70. The company’s 50 day moving average is $49.79 and its 200 day moving average is $56.29.
AnaptysBio (NASDAQ:ANAB – Get Free Report) last posted its earnings results on Thursday, November 12th. The biotechnology company reported $0.11 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.84) by $1.95. The firm had revenue of $30.27 million for the quarter, compared to analysts’ expectations of $25.56 million. AnaptysBio had a net margin of 96.30% and a negative return on equity of 14.28%. On average, equities research analysts anticipate that AnaptysBio, Inc. will post -1.30 EPS for the current year.
Insiders Place Their Bets
In related news, Director Hollings Renton sold 5,000 shares of the business’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $49.87, for a total transaction of $249,350.00. Following the sale, the director owned 10,995 shares in the company, valued at $548,320.65. The trade was a 31.26% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 31.50% of the stock is owned by corporate insiders.
Institutional Trading of AnaptysBio
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Persistent Asset Partners Ltd acquired a new position in shares of AnaptysBio in the second quarter valued at approximately $39,000. Sterling Capital Management LLC boosted its position in AnaptysBio by 847.8% during the 3rd quarter. Sterling Capital Management LLC now owns 654 shares of the biotechnology company’s stock worth $33,000 after buying an additional 585 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new stake in AnaptysBio during the 3rd quarter worth approximately $76,000. State of Alaska Department of Revenue bought a new stake in AnaptysBio during the 3rd quarter worth approximately $85,000. Finally, Group One Trading LLC bought a new stake in AnaptysBio during the 2nd quarter worth approximately $140,000.
About AnaptysBio
AnaptysBio is a biotechnology company focused on developing antibody-based treatments for inflammatory and autoimmune diseases. Its research programs target immune pathways that may be involved in conditions with significant unmet medical needs. The company’s pipeline has included rosnilimab, an investigational antibody designed to activate the PD-1 pathway, and ANB032, an investigational antibody targeting BTLA. AnaptysBio has also developed imsidolimab, an antibody targeting the IL-36 receptor; global rights to that program were licensed to Vanda Pharmaceuticals.
Recommended Stories
- Five stocks we like better than AnaptysBio
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.
